Онкопедиатрия. 2016; 3: 228-239
Особенности нейрогенных опухолей у пациентов с синдромом опсоклонус-миоклонус
https://doi.org/10.15690/onco.v3i3.1602Аннотация
Синдром опсоклонус-миоклонус (ОМС) — редкое неврологическое заболевание, которое в большинстве случаев является паранеопластическим процессом. У детей с ОМС более чем в половине случаев выявляются нейрогенные опухоли, чаще нейробластома (НБ). НБ, ассоциированная с ОМС, имеет анатомические и биологические особенности, которые оказывают влияние на выбор методов диагностики для выявления опухоли и тактики ведения этой группы больных. В данной статье представлены основные характеристики НБ при ОМС, которые легли в основу разработки диагностического алгоритма, направленного на выявление нейрогенных опухолей у пациентов, страдающих ОМС.
Список литературы
1. Качанов Д.Ю., Шаманская Т.В., Малевич О.Б., Варфоломеева С.Р. Синдром опсоклонус- миоклонус и нейробластома (обзор литературы). Российский журнал детской гематологии и онкологии. 2014;1:62–69.
2. Ильина Е.С., Бобылова М.Ю. Энцефалопатия Кинсбурна, или синдром опсоклонус-миоклонус в детском возрасте. Лечащий врач. 2006;5:36–8.
3. Петрухин А.С., Бембеева Р.Ц., Самойлова М.В. Опсоклонус-миоклонус синдром у детей. (Обзор литературы) Журнал невропатологии и психиатрии. 2006;106(2):63–6.
4. Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1– 2):275–82.
5. De Grandis E. Pediatric Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: early diagnosis. In book Neuroblastoma. Pediatric Cancer 1. Hayat MA. (ed.). Springer Science. 2012. P. 21– 29.
6. Pranzatelli MR, Tate ED, Galvan I,Wheeler A. A controlled pilot study of piracetamfor pediatric opsoclonusmyoclonus. Clin Neuropharmacol. 2001;24:352–7.
7. Shimada H. The International Neuroblastoma Pathology Classification. Pathologica. 2003 Oct;95(5):240–1.
8. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–77.
9. NB2004 protocol. http://www.kinderkrebsinfo.de/dlja_specialistov/protokoly_gpoh/pohkinderkrebsinfotherapiestudien/nb2004/index_rus.html
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
11. Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol. 2010 Mar;14(2):156–61.
12. Cushing H, Wolbach SB. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol. 1927 May;3(3):203–216.
13. Hero B, Schleiermacher G. Update onpediatric opsoclonus myoclonus syndrome. Neuropediatrics. 2013;44:324–9.
14. Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol. 2010 Sep;14(5):400–9.
15. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus- myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies- a report from the Children’s Cancer Group Study. Med Pediatr Oncol. 2001 Jun;36(6):612–22.
16. Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch. 2003 Jun;442(6):555–62.
17. Hiyama E, Yokoyama T, Ichikawa T, Hiyama K, Kobayashi M, Tanaka Y, et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer. 1994;74(6):1821–6.
18. Boltshauser E, Deonna T, Hirt HR. Myoclonic encephalopathy of infantsor «dancing eyes syndrome». Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta. 1979 May;34(2):119–33.
19. Takama Y, Yoneda A, Nakamura T, Nakaoka T, Higashio A, Santo K, et al. Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan. Eur J Pediatr Surg. 2016;26(1):54–9.
20. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012 May;97(5):461–3.
21. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39(4):679–88.
22. Parisi MT, Hattner RS, Matthay KK, Berg BO, Sandler ED. Optimized diagnostic strategy for neuroblastoma in opsoclonus- myoclonus. J Nucl Med. 1993;34(11):1922–6.
23. Fendler WP, Melzer HI, Walz C, von Schweinitz D, Coppenrath E, Schmid I, et al. High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1701–10.
24. Georger B, Hero B, Harms D, Grebe J, Scheidhauer K, Bertold F. Metabolic activity and clinical features of primary ganglioneuromas. Cancer. 2001;91(10):1905–13.
25. Качанов Д.Ю., Шаманская Т.В., Коновалов Д.М., Ликарь Ю.Н., Рощин В.Ю., Муфтахова Г.М., Терещенко Г.В., Андреев Е.С., Сухов М.Н., Новичкова Г.А., Варфоломеева С.Р. Ганглионейрома у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2014;13(3):33–41.
26. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr rev. 2003;24:389–427.
27. Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgstrom P, et al. Combined (111)In- pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol. 2000;35:688–91.
28. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTATyr3- octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.
29. Prathamesh J, Vikram L. Somatostatin receptor positron emission tomography/computed tomography (PET/CT) in the evaluation of opsoclonus-myoclonus ataxia syndrome. Indian J Nucl Med. 2013;28(2):108–111.
30. Pranzatelli МR, Tate E. Inflammatory and autoimmune disorders of the nervous system in children. Clinics in Developmental Medicine. 2010;184–185:152–173.
31. Wolff M, Schöning M, Niemann G, Krägeloh-Mann I. Late detection of neuroblastoma in a patient with prolonged cerebellar ataxia without opsoclonus. Neuropediatrics. 2001 Apr;32(2):101–3.
Oncopediatrics. 2016; 3: 228-239
Sympathetic nervous system tumors in children with opsoclonus myoclonus syndrome
https://doi.org/10.15690/onco.v3i3.1602Abstract
References
1. Kachanov D.Yu., Shamanskaya T.V., Malevich O.B., Varfolomeeva S.R. Sindrom opsoklonus- mioklonus i neiroblastoma (obzor literatury). Rossiiskii zhurnal detskoi gematologii i onkologii. 2014;1:62–69.
2. Il'ina E.S., Bobylova M.Yu. Entsefalopatiya Kinsburna, ili sindrom opsoklonus-mioklonus v detskom vozraste. Lechashchii vrach. 2006;5:36–8.
3. Petrukhin A.S., Bembeeva R.Ts., Samoilova M.V. Opsoklonus-mioklonus sindrom u detei. (Obzor literatury) Zhurnal nevropatologii i psikhiatrii. 2006;106(2):63–6.
4. Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1– 2):275–82.
5. De Grandis E. Pediatric Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: early diagnosis. In book Neuroblastoma. Pediatric Cancer 1. Hayat MA. (ed.). Springer Science. 2012. P. 21– 29.
6. Pranzatelli MR, Tate ED, Galvan I,Wheeler A. A controlled pilot study of piracetamfor pediatric opsoclonusmyoclonus. Clin Neuropharmacol. 2001;24:352–7.
7. Shimada H. The International Neuroblastoma Pathology Classification. Pathologica. 2003 Oct;95(5):240–1.
8. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–77.
9. NB2004 protocol. http://www.kinderkrebsinfo.de/dlja_specialistov/protokoly_gpoh/pohkinderkrebsinfotherapiestudien/nb2004/index_rus.html
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
11. Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol. 2010 Mar;14(2):156–61.
12. Cushing H, Wolbach SB. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol. 1927 May;3(3):203–216.
13. Hero B, Schleiermacher G. Update onpediatric opsoclonus myoclonus syndrome. Neuropediatrics. 2013;44:324–9.
14. Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol. 2010 Sep;14(5):400–9.
15. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus- myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies- a report from the Children’s Cancer Group Study. Med Pediatr Oncol. 2001 Jun;36(6):612–22.
16. Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch. 2003 Jun;442(6):555–62.
17. Hiyama E, Yokoyama T, Ichikawa T, Hiyama K, Kobayashi M, Tanaka Y, et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer. 1994;74(6):1821–6.
18. Boltshauser E, Deonna T, Hirt HR. Myoclonic encephalopathy of infantsor «dancing eyes syndrome». Report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta. 1979 May;34(2):119–33.
19. Takama Y, Yoneda A, Nakamura T, Nakaoka T, Higashio A, Santo K, et al. Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan. Eur J Pediatr Surg. 2016;26(1):54–9.
20. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012 May;97(5):461–3.
21. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39(4):679–88.
22. Parisi MT, Hattner RS, Matthay KK, Berg BO, Sandler ED. Optimized diagnostic strategy for neuroblastoma in opsoclonus- myoclonus. J Nucl Med. 1993;34(11):1922–6.
23. Fendler WP, Melzer HI, Walz C, von Schweinitz D, Coppenrath E, Schmid I, et al. High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1701–10.
24. Georger B, Hero B, Harms D, Grebe J, Scheidhauer K, Bertold F. Metabolic activity and clinical features of primary ganglioneuromas. Cancer. 2001;91(10):1905–13.
25. Kachanov D.Yu., Shamanskaya T.V., Konovalov D.M., Likar' Yu.N., Roshchin V.Yu., Muftakhova G.M., Tereshchenko G.V., Andreev E.S., Sukhov M.N., Novichkova G.A., Varfolomeeva S.R. Ganglioneiroma u detei. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2014;13(3):33–41.
26. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr rev. 2003;24:389–427.
27. Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgstrom P, et al. Combined (111)In- pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol. 2000;35:688–91.
28. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTATyr3- octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.
29. Prathamesh J, Vikram L. Somatostatin receptor positron emission tomography/computed tomography (PET/CT) in the evaluation of opsoclonus-myoclonus ataxia syndrome. Indian J Nucl Med. 2013;28(2):108–111.
30. Pranzatelli MR, Tate E. Inflammatory and autoimmune disorders of the nervous system in children. Clinics in Developmental Medicine. 2010;184–185:152–173.
31. Wolff M, Schöning M, Niemann G, Krägeloh-Mann I. Late detection of neuroblastoma in a patient with prolonged cerebellar ataxia without opsoclonus. Neuropediatrics. 2001 Apr;32(2):101–3.
